Corning Announces Extension to HTS Transwell® -96 Permeable Support Products
News Jun 16, 2006
Corning Incorporated has announced the addition of 3.0 µm, 5.0 µm polycarbonate (PC) membrane and 8.0 µm pore polyester (PET) membrane for its HTS Transwell -96 Permeable Support product line.
These pore sizes allow chemotaxis and cell invasion assays in a higher-throughput format, enabling researchers to conduct assays in smaller volumes, test more samples in a single plate, and conserve test reagents and compounds.
"In order for Trevigen, Inc. to provide a robust cell invasion assay system, we evaluated all 96 well plates that were commercially available to perform the assay," said Jay George chief scientific officer, Trevigen, Inc.
"We determined that only the Corning plate met our specific product development needs and would satisfy the needs of our customers."
"The Corning plate was undoubtedly the clear choice for us to provide in our 96 Well BME Cell Invasion Assay kit."
"Corning Life Sciences’ -96 Well is the best all-around for its reliability, large cell growth surface area, well constructed, and designed for easy manual or automatic usage and cost effectiveness."
"Corning Life Sciences has made an ongoing commitment to continually enhance our products with innovative technologies that researchers require to save time and resources and maximize results," said Lydia Kenton, business manager, Cells, Corning Life Sciences.
"Because cell and tissue techniques are becoming such an important part of life science research today, our customers were demanding new technologies that will take the existing methods of growing specialized cell types in an environment closely resembling the in vivo state to the next level."
"The introduction of larger pore inserts to our popular HTS Transwell -96 permeable support product offering clearly combines the best of proven methodologies with new innovation to ensure continued research developments."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.